ArticleOphthalmology and therapy2025
Evaluation of Visual, Refractive, and Functional Outcomes after Implantation of an Extended Depth of Focus Intraocular Lens in Patients with Stable and Mild Glaucoma.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Visual performance of a non-diffractive extended depth of focus IOL in stable early-stage Keratoconus: prospective pilot study.International ophthalmology · 2026Article
- Evaluation of Clinical Outcomes of an Isofocal Optic-Design Intraocular Lens with Double C-Loop Haptics in Eyes with Glaucoma.Journal of clinical medicine · 2026Article
- Visual outcomes in patients with bilateral early to moderate primary open-angle glaucoma following wavefront-shaping partial-range of field-extend intraocular lens implantation.The British journal of ophthalmology · 2026Article
- Factors Affecting Postoperative Satisfaction After Presbyopia-Correcting Intraocular Lens.Journal of clinical medicine · 2026Review
- Clinical Outcomes Following Bilateral Implantation of a Next-Generation Intraocular Lens in Patients with Primary Open Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Visual Outcomes and Reading Performance of a Non-Diffractive EDOF IOL in Chinese Eyes: A Prospective Comparison of Emmetropia and Mini-Monovision Targets.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Comparison of U.S. FDA premarket approval studies between two non-diffractive extended depth of focus lenses (AcrySof IQ Vivity versus TECNIS PureSee).Medical hypothesis, discovery & innovation ophthalmology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe aim of this study is to describe the visual, refractive, functional, and patients' satisfaction outcomes of the AcrySof™ IQ Vivity™ extended depth-of-focus intraocular lens (EDOF IOL) in patients with mild primary open-angle glaucoma (POAG).
methodsThis is an ambispective, multicenter, and descriptive study. Patients with mild and stable POAG for at least 6 months, as well as patients who had the AcrySof™ IQ Vivity™ EDOF IOL implanted were included. Humphrey Field Analyzer III (Carl Zeiss Meditec, Dublin, CA, USA) and Triton optical coherence tomography (Topcon, Japan) were used to evaluate the inclusion criteria. In all cases, the formula used to calculate IOL power was Barrett Universal II. Refractive outcomes and visual acuity at distance, intermediate, and near were evaluated from 3 months postoperatively onward. In addition, monocular and binocular defocus curve and contrast sensitivity (CSV-1000, VectorVision, Greenvile, OH, USA) were assessed. Patient satisfaction was assessed through the Intraocular Lens Satisfaction (IOLSAT) and Questionnaire for Visual Disturbances (QUVID) questionnaires .
resultsIn total, 72 AcrySof™ IQ Vivity™ lenses from 36 patients were enrolled, of which 28 were women. The mean age was 71.61 ± 7.68 years, the mean thickness of the retinal nerve fiber layer (RNFL) was 79.24 ± 14.96 µm, the mean intraocular pressure (IOP) was 16.88 ± 3.09 mmHg, and the mean number of topical anti-glaucoma medication was 0.89 ± 0.95. Binocular corrected distance visual acuity (CDVA), binocular corrected intermediate visual acuity (CIVA), and binocular corrected near visual acuity (CNVA) were 0.00 ± 0.12, 0.16 ± 0.14, and 0.24 ± 0.11 LogMAR, respectively. Spherical equivalent was -0.27 ± 0.33 diopters (D). In addition, 86.11% of eyes were within ± 0.5 D and 95.83% were within ± 1.0 D. The binocular defocus curve shows a peak of maximum visual acuity (VA) at 0 D (0.00 ± 0.11 LogMAR) and smooth curve at intermediate (66 cm/-1.5 D) 0.11 ± 0.09 LogMAR and near distance (40 cm/-2.5 D) 0.36 ± 0.18 LogMAR. Binocular contrast sensitivity showed a decrease in high spatial frequencies compared with low spatial frequencies. The IOLSAT revealed that in bright light conditions, 88.89%, 91.67%, and 63.89% of patients "never" or "rarely" need glasses at far, arm's length, and near distances, respectively. In addition, according to the QUVID, 97.06% of patients "never" report shadow areas.
conclusionsThe new AcrySof™ IQ Vivity™ EDOF IOL seems to provide good visual outcomes at distance, intermediate, and near vision, with an adequate contrast sensitivity, defocus curve, a low rate of visual disturbances and high visual satisfaction in patients with mild and stable POAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.